Anlotinib non-inferior to bevacizumab in first-line treatment of mCRC

The randomised, multicentre phase 3 ANCHOR trial demonstrated that the oral multi-target tyrosine kinase inhibitor (TKI) anlotinib is non-inferior to bevacizumab when each is combined with capecitabine and oxaliplatin (CAPOX) in the first-line treatment of RAS/BRAF wildtype, unresectable metastatic colorectal cancer (mCRC). These findings may expand treatment options for patients by offering an effective oral anti-angiogenic alternative to intravenous anti-VEGF therapy. The open-label ANCHOR trial (NCT04854668), presented by Prof. Ke-Feng Ding (Zhejiang University, China), randomised treatment-naïve participants with confirmed RAS/BRAF wildtype mCRC and multidisciplinary team-determined unresectable metastases (n=748) 1:1 to anlotinib or bevacizumab alongside CAPOX [1,2]. Anlotinib is a multi-targeted TKI that inhibits VEGFR 1/2/3, FGFR 1–4, and PDGFR α/β. The primary endpoint was...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025